Natural Killer (NK) Cell Therapeutics Market - A Global and Regional Analysis: Focus on NK Cell Therapy Type, Indication, Country, Pipeline Analysis, and Competitive Landscape - Analysis and Forecast, 2022-2032
Description
Natural Killer (NK) Cell Therapeutics Market - A Global and Regional Analysis: Focus on NK Cell Therapy Type, Indication, Country, Pipeline Analysis, and Competitive Landscape - Analysis and Forecast, 2022-2032
Global NK Cell Therapeutics Market: Industry Overview
The global NK cell therapeutics market is expected to reach $5,676.1 million in 2032 from $297.2 million in 2024 at a CAGR of 44.59% during the forecast period 2024-2032. The growth in the global NK cell therapeutics market is expected to be driven by the rising in the number of clinical trials and the increasing incidence and prevalence of cancer cases.
Market Lifecycle Stage
The global NK cell therapeutics market is at a very nascent stage. Currently, there is no approved NK cell therapy in the market. Many biopharmaceutical companies are trying to research and develop new immunotherapies, especially NK cell therapies which would be cost-effective and hence, could act as a next-generation medication for cancer and other acute infectious indications. For instance, major players such as Affimed N.V., GC Cell (GC Biopharma corp.), Glycostem Therapeutics B.V., and Takeda Pharmaceutical Company Limited are investing heavily in clinical trials for their respective therapeutic candidates for various indications such as acute myeloid leukemia (AML), B-cell non-Hodgkin’s lymphoma (NHL) - relapsed or refractory, hepatocellular carcinoma (HCC), and peripheral T-cell lymphoma. Increasing funding and investments in research and development is one of the major opportunities in the global NK cell therapeutics market.
Impact
With an increased worldwide focus on researching NK cell therapies, the major market players are developing novel therapeutics, such as NK cells therapy (unmodified), CAR-NK cells therapy (modified), and NK cell engager. For instance, currently, there are 79 ongoing clinical trials for NK cell therapeutics for different types of indications such as acute myeloid leukemia, hematologic malignancies, hepatocellular carcinoma, and peripheral T-cell lymphoma, which is significantly impacting the growth of NK cell therapeutics market.
Immunotherapies are more prominent in countries such as the U.S., the U.K., and South Korea. Moreover, the presence of major market players such as Affimed N.V., Fate Therapeutics, Inc., Gamida Cell Ltd., GC Cell (GC Biopharma corp.), Nkarta, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited in eight major countries, including the U.S., EU5 (U.K., Germany, France, Spain, Italy), Japan, and South Korea have a positive impact on the market growth.
Impact of COVID-19
Due to the pandemic, governments across the globe enforced lockdowns which significantly hampered the research and clinical development of NK cell therapeutics. This situation was majorly witnessed till Q2 2021, which created a negative impact on the global NK cell therapeutics market, resulting in a decline in preclinical and clinical trials of the product candidates. The major reason has been the difficulty in patient recruitment for the ongoing clinical trials, which will have an impact on the launch timelines of the drugs.
However, it is worth mentioning here that with the ease of restrictions after Q2 2021, the market for NK cell therapy has gained significant momentum and is anticipated to grow during the forecast period 2024-2032.
The COVID-19 pandemic has exerted tremendous strain on the research and clinical development of NK cell therapeutics. Companies operating in the field of NK cell therapies have changed their focus on the research and development of drugs used for COVID-19 treatment to help governments and communities establish a new normal across the globe.
This has resulted in the delayed launch of emerging therapies due to a shift in priorities on account of the COVID-19 pandemic. In addition, pharmaceutical companies are diverting their financial resources to develop and repurpose existing drug molecules for the prevention and treatment of COVID-19. This strategy has been adopted by most pharmaceutical companies to generate high revenue from the sale of COVID-19 drugs. These factors exert a combinatorial effect on the development and launch of emerging NK therapies.
For instance, Affimed N.V. faced challenges in the patients’ enrolment due to the COVID-19 pandemic for the investigation of AFM13 therapy in patients suffering from transformed mycosis fungoides (TMF). Hence, the company decided to halt the trial of AFM13 for patients with TMF. Similarly, Celularity Inc. also faced difficulty in the enrolment of the patients for its phase 1 clinical trial of CYNK-001 in early 2020 and again in mid-2021, which was for the indication of acute myeloid leukemia. Furthermore, Nkarta, Inc.’s few clinical trial sites have restricted enrollment for the clinical trials temporarily to prioritize hospital beds for patients suffering from COVID-19. Also, enrolment delays were experienced due to the supply chain and operational disruptions experienced owing to COVID-19. This led to some delays in gathering up the clinical sites for the clinical trials of NKX101 and NKX019.
Market Segmentation
Segmentation 1: by Therapy Type
Segmentation 2: by Pipeline Products
Segmentation 3: by Indication
Segmentation 4: by Country
Recent Developments in the Global NK Cell Therapeutics Market
Following are the demand drivers for the global NK cell therapeutics market:
Product/Innovation Strategy: The product segment helps the reader to understand the pipeline products in the market that are in different stages of clinical trials. Additionally, it helps to understand the multiple indications for which the trials are going on along with their route of administration. Moreover, the study provides the reader with a detailed understanding of four different indications such as acute myeloid leukemia (AML), B-cell non-Hodgkin’s lymphoma (NHL) - relapsed or refractory, hepatocellular carcinoma (HCC), and peripheral T-cell lymphoma.
Growth/Marketing Strategy: The global NK cell therapeutics market has seen major development by key players operating in the market, such as regulatory and legal activities, product approvals, partnerships and alliances, and merger and acquisition activities. The favored strategy for the companies has been clinical developments along with regulatory and legal activities. The companies are focusing on enhancing the clinical trials of the NK cell therapies so as to receive the regulatory authorizations as much as possible to strengthen their position in the market. For instance, in January 2020, Fate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application for FT536, a chimeric antigen receptor (CAR) NK cell candidate. The company further plans to focus on the clinical investigation of FT536 as a monotherapy and combination for the treatment of multiple solid tumor indications.
Competitive Strategy: Key players in the global NK cell therapeutics market analyzed and profiled in the study involve immunotherapies, especially NK cell therapy. Moreover, a detailed competitive benchmarking of players operating in the global NK cell therapeutics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, pipeline product portfolio, and market penetration.
Some prominent names established in this market are:
*PDF email from publisher allows for 1-3 users, with permission to print*
Global NK Cell Therapeutics Market: Industry Overview
The global NK cell therapeutics market is expected to reach $5,676.1 million in 2032 from $297.2 million in 2024 at a CAGR of 44.59% during the forecast period 2024-2032. The growth in the global NK cell therapeutics market is expected to be driven by the rising in the number of clinical trials and the increasing incidence and prevalence of cancer cases.
Market Lifecycle Stage
The global NK cell therapeutics market is at a very nascent stage. Currently, there is no approved NK cell therapy in the market. Many biopharmaceutical companies are trying to research and develop new immunotherapies, especially NK cell therapies which would be cost-effective and hence, could act as a next-generation medication for cancer and other acute infectious indications. For instance, major players such as Affimed N.V., GC Cell (GC Biopharma corp.), Glycostem Therapeutics B.V., and Takeda Pharmaceutical Company Limited are investing heavily in clinical trials for their respective therapeutic candidates for various indications such as acute myeloid leukemia (AML), B-cell non-Hodgkin’s lymphoma (NHL) - relapsed or refractory, hepatocellular carcinoma (HCC), and peripheral T-cell lymphoma. Increasing funding and investments in research and development is one of the major opportunities in the global NK cell therapeutics market.
Impact
With an increased worldwide focus on researching NK cell therapies, the major market players are developing novel therapeutics, such as NK cells therapy (unmodified), CAR-NK cells therapy (modified), and NK cell engager. For instance, currently, there are 79 ongoing clinical trials for NK cell therapeutics for different types of indications such as acute myeloid leukemia, hematologic malignancies, hepatocellular carcinoma, and peripheral T-cell lymphoma, which is significantly impacting the growth of NK cell therapeutics market.
Immunotherapies are more prominent in countries such as the U.S., the U.K., and South Korea. Moreover, the presence of major market players such as Affimed N.V., Fate Therapeutics, Inc., Gamida Cell Ltd., GC Cell (GC Biopharma corp.), Nkarta, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited in eight major countries, including the U.S., EU5 (U.K., Germany, France, Spain, Italy), Japan, and South Korea have a positive impact on the market growth.
Impact of COVID-19
Due to the pandemic, governments across the globe enforced lockdowns which significantly hampered the research and clinical development of NK cell therapeutics. This situation was majorly witnessed till Q2 2021, which created a negative impact on the global NK cell therapeutics market, resulting in a decline in preclinical and clinical trials of the product candidates. The major reason has been the difficulty in patient recruitment for the ongoing clinical trials, which will have an impact on the launch timelines of the drugs.
However, it is worth mentioning here that with the ease of restrictions after Q2 2021, the market for NK cell therapy has gained significant momentum and is anticipated to grow during the forecast period 2024-2032.
The COVID-19 pandemic has exerted tremendous strain on the research and clinical development of NK cell therapeutics. Companies operating in the field of NK cell therapies have changed their focus on the research and development of drugs used for COVID-19 treatment to help governments and communities establish a new normal across the globe.
This has resulted in the delayed launch of emerging therapies due to a shift in priorities on account of the COVID-19 pandemic. In addition, pharmaceutical companies are diverting their financial resources to develop and repurpose existing drug molecules for the prevention and treatment of COVID-19. This strategy has been adopted by most pharmaceutical companies to generate high revenue from the sale of COVID-19 drugs. These factors exert a combinatorial effect on the development and launch of emerging NK therapies.
For instance, Affimed N.V. faced challenges in the patients’ enrolment due to the COVID-19 pandemic for the investigation of AFM13 therapy in patients suffering from transformed mycosis fungoides (TMF). Hence, the company decided to halt the trial of AFM13 for patients with TMF. Similarly, Celularity Inc. also faced difficulty in the enrolment of the patients for its phase 1 clinical trial of CYNK-001 in early 2020 and again in mid-2021, which was for the indication of acute myeloid leukemia. Furthermore, Nkarta, Inc.’s few clinical trial sites have restricted enrollment for the clinical trials temporarily to prioritize hospital beds for patients suffering from COVID-19. Also, enrolment delays were experienced due to the supply chain and operational disruptions experienced owing to COVID-19. This led to some delays in gathering up the clinical sites for the clinical trials of NKX101 and NKX019.
Market Segmentation
Segmentation 1: by Therapy Type
- NK Cell Therapy (Unmodified)
- CAR-NK Cell Therapy (Modified)
- NK Cell Engagers
Segmentation 2: by Pipeline Products
- AFM13
- MG4101
- GTA002 (oNKordA)
- TAK-007
Segmentation 3: by Indication
- Acute Myeloid Leukemia
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
- Hepatocellular Carcinoma
- Peripheral T-Cell Lymphoma
Segmentation 4: by Country
- U.S.
- U.K
- France
- Spain
- Italy
- Germany
- Japan
- South Korea
Recent Developments in the Global NK Cell Therapeutics Market
- In April 2022, Affimed N.V. announced data on the dose-escalation study of its innate cell engager AFM24 in patients with EGFR-positive solid tumors. As per the data, AFM24 showed a well-managed safety profile.
- In April 2022, Nkarta, Inc. announced positive preliminary data of phase 1 of its two cell therapy candidates, NKX101 and NKX019, of chimeric antigen receptor (CAR) natural killer (NK) cell therapy. The results of the study showed the safety advantages of NK cells with an off-the-shelf modality which was designed to increase the benefits of cell therapy.
- In January 2022, Affimed N.V. announced the completion of the participants for its phase 2 study for its lead product AFM13 as a monotherapy for patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL).
- In December 2021, Innate Pharma SA disclosed that the first patient received treatment in a phase 1/2 clinical trial of IPH6101/SAR443579, a lead molecular target for NK cells that targets NKp46/CD16, in patients with chronic myelogenous leukemia (CRML), B-cell acute lymphoblastic leukemia (B-ALL), or high-risk myelodysplastic syndrome (HR-MDS). The trial is being conducted in collaboration with Sanofi S.A.
Following are the demand drivers for the global NK cell therapeutics market:
- Rising Number of Clinical Trials
- Increasing Incidence and Prevalence of Cancer
- Lack of Specificity and Poor In Vivo Survival of the NK Cells
- High Cost of Immunotherapy Treatment Associated with Cancer
Product/Innovation Strategy: The product segment helps the reader to understand the pipeline products in the market that are in different stages of clinical trials. Additionally, it helps to understand the multiple indications for which the trials are going on along with their route of administration. Moreover, the study provides the reader with a detailed understanding of four different indications such as acute myeloid leukemia (AML), B-cell non-Hodgkin’s lymphoma (NHL) - relapsed or refractory, hepatocellular carcinoma (HCC), and peripheral T-cell lymphoma.
Growth/Marketing Strategy: The global NK cell therapeutics market has seen major development by key players operating in the market, such as regulatory and legal activities, product approvals, partnerships and alliances, and merger and acquisition activities. The favored strategy for the companies has been clinical developments along with regulatory and legal activities. The companies are focusing on enhancing the clinical trials of the NK cell therapies so as to receive the regulatory authorizations as much as possible to strengthen their position in the market. For instance, in January 2020, Fate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application for FT536, a chimeric antigen receptor (CAR) NK cell candidate. The company further plans to focus on the clinical investigation of FT536 as a monotherapy and combination for the treatment of multiple solid tumor indications.
Competitive Strategy: Key players in the global NK cell therapeutics market analyzed and profiled in the study involve immunotherapies, especially NK cell therapy. Moreover, a detailed competitive benchmarking of players operating in the global NK cell therapeutics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, pipeline product portfolio, and market penetration.
Some prominent names established in this market are:
- Affimed N.V.
- Century Therapeutics, Inc.
- Celularity Inc.
- Cytovac A/S
- Dragonfly Therapeutics, Inc.
- Fate Therapeutics, Inc.
- Gamida Cell Ltd.
- GC Cell (GC Biopharma corp.)
- Glycostem Therapeutics B.V.
- ImmunityBio, Inc.
- Innate Pharma SA
- Nkarta, Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- VaxCell Biotherapeutics Co., Ltd.
- Acepodia Inc.
- iCell Gene Therapeutics
- Senti Biosciences
- Shoreline Biosciences
*PDF email from publisher allows for 1-3 users, with permission to print*
Table of Contents
207 Pages
- 1 Market
- 1.1 Product Definition
- 1.2 Inclusion and Exclusion Criteria
- 1.3 Market Scope
- 1.3.1 Key Questions Answered
- 1.4 Research Methodology
- 1.4.1 Global NK Cell Therapeutics Market: Research Methodology
- 1.4.2 Primary Data Sources
- 1.4.3 Secondary Data Sources
- 1.5 Market Estimation Model
- 1.6 Criteria for Company Profiling
- 1.7 Market Overview
- 1.7.1 Introduction
- 1.7.2 Evolution of NK Cell Therapeutics
- 1.7.3 Types of NK Cell Therapeutics
- 1.7.4 Source of NK Cell Therapeutics
- 1.7.5 Mechanism of Action: NK Cell Therapies
- 1.7.5.1 Application of NK Cell Therapeutics in Disease Areas
- 1.7.5.1.1 Cancer
- 1.7.5.1.2 Acute Infectious Disease
- 1.7.6 Role of NK Cell Therapeutics in COVID-19
- 1.7.7 Comparison between Car T-Cell Therapy and NK Cell Therapy
- 1.7.8 Advantages and Limitations of NK Cell Therapeutics
- 1.7.9 Current Market Size and Growth Potential, $Million, 2022-2032
- 1.7.10 COVID-19 Impact on Global NK Cell Therapeutics Market
- 1.7.10.1 Overview
- 1.7.10.2 Research and Clinical Development Interruption in Global NK Cell Therapeutics Market
- 2 Pipeline Analysis
- 2.1 Global NK Cell Therapeutics Market Pipeline Analysis
- 2.2 Probable Potential First Entrants to Global NK Cell Therapeutics Market
- 2.2.1 Overview
- 2.2.2 AFM13
- 2.2.2.1 Product Profile
- 2.2.2.2 AFM13 Phase II Study Design
- 2.2.3 MG4101
- 2.2.3.1 Product Profile
- 2.2.3.2 MG4101 Phase II Study Design
- 2.2.4 GTA002 (oNKord)
- 2.2.4.1 Product Profile
- 2.2.4.2 GTA002 (oNKord) Phase II Study Design
- 2.2.5 TAK-007
- 2.2.5.1 Product Profile
- 2.2.5.2 TAK-007 Phase II Study Design
- 3 Industry Analysis
- 3.1 Overview
- 3.2 Legal Requirements and Framework in the U.S.
- 3.2.1 Clinical Trial Authorization
- 3.2.2 Marketing Authorization
- 3.2.3 U.S. Food and Drug Administration Guidelines for Biologics License Application (BLA)
- 3.2.4 Post-Authorization Regulations
- 3.3 Legal Requirements and Frameworks in Europe
- 3.4 Legal Requirements and Framework in Japan
- 3.5 Legal Requirements and Framework in South Korea
- 3.6 Reimbursement Scenario in the U.S.
- 3.7 Reimbursement Scenario in Europe
- 4 Market Dynamics
- 4.1 Overview
- 4.2 Impact Analysis
- 4.3 Market Drivers
- 4.3.1 Rising Number of Clinical Trials
- 4.3.2 Increasing Incidence and Prevalence of Cancer
- 4.4 Market Restraints
- 4.4.1 Lack of Specificity and Poor In Vivo Survival of the NK Cells
- 4.4.2 High Cost of Immunotherapy Treatment Associated with Cancer
- 4.5 Market Opportunities
- 4.5.1 Increasing Funding and Investment
- 4.5.2 Rising Number of Partnerships and Collaborations
- 5 Market Analysis
- 5.1 Global NK Cell Therapeutics Market (by Therapy Type), $Million, 2024-2032
- 5.1.1 Overview
- 5.1.2 NK Cell Therapy (Unmodified)
- 5.1.3 CAR-NK Cell Therapy (Modified)
- 5.1.4 NK Cell Engagers
- 5.2 Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024-2032
- 5.2.1 Overview
- 5.2.2 AFM13
- 5.2.3 MG4101
- 5.2.4 GTA002 (oNKord)
- 5.2.5 TAK-007
- 5.3 Global NK Cell Therapeutics Market (by Indication), $Million, 2024-2032
- 5.3.1 Overview
- 5.3.2 Acute Myeloid Leukemia
- 5.3.3 Hepatocellular Carcinoma
- 5.3.4 Peripheral T-Cell Lymphoma
- 5.3.5 Relapsed or Refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
- 5.4 Global NK Cell Therapeutics Market (by Country), $Million, 2024-2032
- 5.4.1 Overview
- 5.4.2 U.S.
- 5.4.3 U.K.
- 5.4.4 Germany
- 5.4.5 France
- 5.4.6 Italy
- 5.4.7 Spain
- 5.4.8 Japan
- 5.4.9 South Korea
- 6 Market - Competitive Benchmarking & Company Profiles
- 6.1 Competitive Landscape
- 6.1.1 Clinical Developments
- 6.1.2 Regulatory and Legal Activities
- 6.1.3 Partnerships and Alliances
- 6.1.4 Funding Activities
- 6.1.4.1 Institutional Fundings
- 6.1.5 Business Expansions
- 6.2 Company Profiles
- 6.2.1 Overview
- 6.2.2 Affimed N.V.
- 6.2.2.1 Company Overview
- 6.2.2.2 Role of Affimed N.V. in the Global NK Cell Therapeutics Market
- 6.2.2.3 Key Competitors of the Company
- 6.2.2.4 Financials
- 6.2.2.5 Key Insight about the Financial Health of the Company
- 6.2.2.6 Business Strategies
- 6.2.2.7 Analyst Perspective
- 6.2.3 Century Therapeutics, Inc.
- 6.2.3.1 Company Overview
- 6.2.3.2 Role of Century Therapeutics, Inc. in the Global NK Cell Therapeutics Market
- 6.2.3.3 Key Competitors of the Company
- 6.2.3.4 Financials
- 6.2.3.5 Key Insight about the Financial Health of the Company
- 6.2.3.6 Business Strategies
- 6.2.3.7 Analyst Perspective
- 6.2.4 Celularity Inc.
- 6.2.4.1 Company Overview
- 6.2.4.2 Role of Celularity Inc. in the Global NK Cell Therapeutics Market
- 6.2.4.3 Key Competitors of the Company
- 6.2.4.4 Financials
- 6.2.4.5 Key Insight about the Financial Health of the Company
- 6.2.4.6 Business Strategies
- 6.2.4.7 Analyst Perspective
- 6.2.5 Cytovac A/S
- 6.2.5.1 Company Overview
- 6.2.5.2 Role of Cytovac A/S in Global NK Cell Therapeutics Market
- 6.2.5.3 Key Competitors of the Company
- 6.2.5.4 Analyst Perspective
- 6.2.6 Dragonfly Therapeutics, Inc.
- 6.2.6.1 Company Overview
- 6.2.6.2 Role of Dragonfly Therapeutics, Inc. in the Global NK Cell Therapeutics Market
- 6.2.6.3 Key Competitors of the Company
- 6.2.6.4 Business Strategies
- 6.2.6.5 Analyst Perspective
- 6.2.7 Fate Therapeutics, Inc.
- 6.2.7.1 Company Overview
- 6.2.7.2 Role of Fate Therapeutics, Inc. in the Global NK Cell Therapeutics Market
- 6.2.7.3 Key Competitors of the Company
- 6.2.7.4 Financials
- 6.2.7.5 Key Insight about the Financial Health of the Company
- 6.2.7.6 Business Strategies
- 6.2.7.7 Analyst Perspective
- 6.2.8 Gamida Cell Ltd.
- 6.2.8.1 Company Overview
- 6.2.8.2 Role of Gamida Cell Ltd. in the Global NK Cell Therapeutics Market
- 6.2.8.3 Key Competitors of the Company
- 6.2.8.4 Financials
- 6.2.8.5 Key Insight about the Financial Health of the Company
- 6.2.8.6 Analyst Perspective
- 6.2.9 GC Cell (GC Biopharma corp.)
- 6.2.9.1 Company Overview
- 6.2.9.2 Role of GC Cell (GC Biopharma corp.) in Global NK Cell Therapeutics Market
- 6.2.9.3 Key Competitors of the Company
- 6.2.9.4 Financials
- 6.2.9.5 Business Strategies
- 6.2.9.6 Analyst Perspective
- 6.2.10 Glycostem Therapeutics B.V.
- 6.2.10.1 Company Overview
- 6.2.10.2 Role of Glycostem Therapeutics B.V. in the Global NK Cell Therapeutics Market
- 6.2.10.3 Key Competitors of the Company
- 6.2.10.4 Business Strategies
- 6.2.10.5 Analyst Perspective
- 6.2.11 ImmunityBio, Inc.
- 6.2.11.1 Company Overview
- 6.2.11.2 Role of ImmunityBio, Inc. in the Global NK Cell Therapeutics Market
- 6.2.11.3 Key Competitors of the Company
- 6.2.11.4 Financials
- 6.2.11.5 Key Insight about the Financial Health of the Company
- 6.2.11.6 Business Strategies
- 6.2.11.7 Analyst Perspective
- 6.2.12 Innate Pharma SA
- 6.2.12.1 Company Overview
- 6.2.12.2 Role of Innate Pharma SA in the Global NK Cell Therapeutics Market
- 6.2.12.3 Key Competitors of the Company
- 6.2.12.4 Financials
- 6.2.12.5 Key Insight about the Financial Health of the Company
- 6.2.12.6 Business Strategies
- 6.2.12.7 Analyst Perspective
- 6.2.13 Nkarta, Inc.
- 6.2.13.1 Company Overview
- 6.2.13.2 Role of Nkarta, Inc. in the Global NK Cell Therapeutics Market
- 6.2.13.3 Key Competitors of the Company
- 6.2.13.4 Financials
- 6.2.13.5 Key Insight about the Financial Health of the Company
- 6.2.13.6 Business Strategies
- 6.2.13.7 Analyst Perspective
- 6.2.14 Sanofi S.A.
- 6.2.14.1 Company Overview
- 6.2.14.2 Role of Sanofi S.A. in the Global NK Cell Therapeutics Market
- 6.2.14.3 Key Competitors of the Company
- 6.2.14.4 Financials
- 6.2.14.5 Key Insight about the Financial Health of the Company
- 6.2.14.6 Business Strategies
- 6.2.14.7 Analyst Perspective
- 6.2.15 Takeda Pharmaceutical Company Limited
- 6.2.15.1 Company Overview
- 6.2.15.2 Role of Takeda Pharmaceutical Company Limited in the Global NK Cell Therapeutics Market
- 6.2.15.3 Key Competitors of the Company
- 6.2.15.4 Financials
- 6.2.15.5 Key Insight about the Financial Health of the Company
- 6.2.15.6 Analyst Perspective
- 6.2.16 VaxCell Biotherapeutics Co., Ltd.
- 6.2.16.1 Company Overview
- 6.2.16.2 Role of VaxCell Biotherapeutics Co., Ltd. in the Global NK Cell Therapeutics Market
- 6.2.16.3 Key Competitors of the Company
- 6.2.16.4 Analyst Perspective
- 6.3 Emerging Companies
- 6.3.1 Overview
- 6.3.2 Acepodia Inc.
- 6.3.2.1 Company Overview
- 6.3.2.2 Role of Acepodia Inc. in the Global NK Cell Therapeutics Market
- 6.3.2.3 Key Competitors of the Company
- 6.3.2.4 Analyst Perspective
- 6.3.3 iCell Gene Therapeutics
- 6.3.3.1 Company Overview
- 6.3.3.2 Role of iCell Gene Therapeutics in the Global NK Cell Therapeutics Market
- 6.3.3.3 Key Competitors of the Company
- 6.3.3.4 Analyst Perspective
- 6.3.4 Senti Biosciences
- 6.3.4.1 Company Overview
- 6.3.4.2 Role of Senti Biosciences in Global NK Cell Therapeutics Market
- 6.3.4.3 Key Competitors of the Company
- 6.3.4.4 Analyst Perspective
- 6.3.5 Shoreline Biosciences
- 6.3.5.1 Company Overview
- 6.3.5.2 Role of Shoreline Biosciences in the Global NK Cell Therapeutics Market
- 6.3.5.3 Key Competitors of the Company
- 6.3.5.4 Analyst Perspective
- List of Figures
- Figure 1: Immunotherapies Approved by the U.S. Food and Drug Administration (FDA), 2011-2022
- Figure 2: NK Cell Therapeutics Clinical Trials (by Phase), 2022
- Figure 3: NK Cell Therapeutics Clinical Trials (by Indication), 2022
- Figure 4: Global NK Cell Therapeutics Market Growth Revenue, $Million, 2024-2032
- Figure 5: Global NK Cell Therapeutics Market (by NK Cell Therapeutics Type), $Million, 2024, 2025, 2026, and 2032
- Figure 6: Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024, 2025, 2026, and 2032
- Figure 7: Global NK Cell Therapeutics Market (by Indication), $Million, 2024, 2025, 2026, and 2032
- Figure 8: Global NK Cell Therapeutics Market (by Region), $Million, 2024-2032
- Figure 9: Global NK Cell Therapeutics Market Segmentation
- Figure 10: Global NK Cell Therapeutics Market Methodology
- Figure 11: Primary Research Methodology
- Figure 12: Epidemiology-Based Approach
- Figure 13: Types of Immunotherapies
- Figure 14: Types of NK Cells
- Figure 15: Academic NK Clinical Milestones
- Figure 16: Types of NK Cell Therapeutics
- Figure 17: NK Cell Interacts with Healthy Cell
- Figure 18: NK Cell Interacts with Target Cell
- Figure 19: Applications of NK Cell Therapeutics in Disease Areas
- Figure 20: Global NK Cell Therapeutics Market Growth Revenue, $Million, 2024-2032
- Figure 21: Areas of Disruption in Clinical Development
- Figure 22: NK Cell Therapeutics Clinical Trials (by Phase), 2022
- Figure 23: NK Cell Therapeutics Clinical Trials (by Indication), 2022
- Figure 24: AFM13 Phase II Clinical Design for Peripheral T-Cell Lymphoma
- Figure 25: MG4101 Phase II Clinical Design for Hepatocellular Carcinoma, Treatment Group and Control Group
- Figure 26: MG4101 Phase II Clinical Design for Hepatocellular Carcinoma
- Figure 27: GTA002 (oNKord) Phase II WiNK Trial Stages for Acute Myeloid Leukemia
- Figure 28: GTA002 (oNKord) Phase II Clinical Design for Acute Myeloid Leukemia
- Figure 29: TAK-007 Phase II Trial Stages for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
- Figure 30: TAK-007 Phase II Clinical Design for Relapsed or Refractory (r/r) B-Cell Non-Hodgkin’s Lymphoma (NHL)
- Figure 31: Clinical Trial Authorization for NK Cell Therapeutics
- Figure 32: Process for Obtaining Marketing Authorization
- Figure 33: Procedures Offered by the Food and Drug Administration (FDA) for Drugs Intended to Treat Serious Health Conditions
- Figure 34: U.S. Food and Drug Administration Review Timeline
- Figure 35: EMA Review Timeline
- Figure 36: South Korea Approval Process from Development to Authorization
- Figure 37: Reimbursement Scenarios in the U.S. for CAR T-Cell Therapy (Initial and Current Approach)
- Figure 38: Current Reimbursement Scenario in Europe
- Figure 39: Impact Analysis of Market Drivers
- Figure 40: Number of Clinical Trials for NK Cell Therapies (by Year)
- Figure 41: Number of Clinical Trials for NK Cell Therapies (by Major Players)
- Figure 42: Global Cancer Incidence, 2017-2018
- Figure 43: Cancer Incidence (by Region), 2017-2018
- Figure 44: Global NK Cell Therapeutics Market (by Therapy Type)
- Figure 45: Global NK Cell Therapeutics Market (by Therapy Type), $Million, 2024, 2025, 2026, and 2032
- Figure 46: NK Cell Therapy (Unmodified) Market, $Million, 2024-2032
- Figure 47: CAR-NK Cell Therapy (Modified) Market, $Million, 2025-2032
- Figure 48: NK Cell Engagers Market, $Million, 2026-2032
- Figure 49: Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024, 2025, 2026, and 2032
- Figure 50: Global Revenue for AFM13, $Million, 2026-2032
- Figure 51: Global Revenue for MG4101, $Million, 2026-2032
- Figure 52: Global Revenue for GTA002 (oNKordA), $Million, 2024-2032
- Figure 53: Global Revenue for TAK-007, $Million, 2025-2032
- Figure 54: Global NK Cell Therapeutics Market (by Indication), $Million, 2024, 2025, 2026, and 2032
- Figure 55: Global NK Cell Therapeutics Market (by Acute Myeloid Leukemia), $Million, 2024-2032
- Figure 56: Global NK Cell Therapeutics Market (by Hepatocellular Carcinoma), $Million, 2026-2032
- Figure 57: Global NK Cell Therapeutics Market (by Peripheral T-Cell Lymphoma), $Million, 2026-2032
- Figure 58: Global NK Cell Therapeutics Market (by Relapsed or Refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)), $Million, 2026-2032
- Figure 59: Global NK Cell Therapeutics Market (by Region)
- Figure 60: Global NK Cell Therapeutics Market (by Region), $Million, 2024-2032
- Figure 61: Global NK Cell Therapeutics Market (by Country), $Million, 2024-2032
- Figure 62: U.S. NK Cell Therapeutics Market, $Million, 2024-2032
- Figure 63: U.K. NK Cell Therapeutics Market, $Million, 2024-2032
- Figure 64: Germany NK Cell Therapeutics Market, $Million, 2024-2032
- Figure 65: France NK Cell Therapeutics Market, $Million, 2024-2032
- Figure 66: Italy NK Cell Therapeutics Market, $Million, 2024-2032
- Figure 67: Spain NK Cell Therapeutics Market, $Million, 2024-2032
- Figure 68: Japan NK Cell Therapeutics Market, $Million, 2024-2032
- Figure 69: South Korea NK Cell Therapeutics Market, $Million, 2024-2032
- Figure 70: Share of Key Developments and Strategies, January 2019-April 2022
- Figure 71: Share of Regulatory and Legal Activities (by Company), January 2019-April 2022
- Figure 72: Share of Partnerships and Alliances (by Company), January 2019-April 2022
- Figure 73: Share of Funding Activities (by Company), January 2019-April 2022
- Figure 74: Share of Business Expansions (by Company), January 2019-April 2022
- Figure 75: Affimed N.V.: Preclinical and Clinical Assets
- Figure 76: Affimed N.V.: Overall Financials, $Million, 2019-2021
- Figure 77: Affimed N.V.: Revenue (by Region), $Million, 2019-2021
- Figure 78: Affimed N.V.: R&D Expenditure, $Million, 2019-2021
- Figure 79: Affimed N.V: R&D Expenditure (by Product), $Million, 2019-2021
- Figure 80: Century Therapeutics, Inc.: Preclinical and Clinical Assets
- Figure 81: Century Therapeutics, Inc.: Overall Financials, $Million, 2020-2021
- Figure 82: Century Therapeutics, Inc.: R&D Expenditure, $Million, 2020-2021
- Figure 83: Celularity Inc.: Preclinical and Clinical Assets
- Figure 84: Celularity Inc. Overall Financials, $Million, 2020-2021
- Figure 85: Celularity Inc.: Revenue (by Segment), $Million, 2020-2021
- Figure 86: Celularity Inc.: R&D Expenditure, $Million, 2020-2021
- Figure 87: Cytovac A/S: Preclinical and Clinical Assets
- Figure 88: Dragonfly Therapeutics, Inc.: Preclinical and Clinical Assets
- Figure 89: Fate Therapeutics, Inc.: Preclinical and Clinical Assets
- Figure 90: Fate Therapeutics, Inc. Overall Financials, $Million, 2019-2021
- Figure 91: Fate Therapeutics, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 92: Gamida Cell Ltd.: Preclinical and Clinical Assets
- Figure 93: Gamida Cell Ltd. Overall Financials, $Million, 2019-2021
- Figure 94: Gamida Cell Ltd.: R&D Expenditure, $Million, 2019-2021
- Figure 95: GC Cell (GC Biopharma corp.) Preclinical and Clinical Assets
- Figure 96: GC Cell (GC Biopharma corp.) Overall Financials, $Million, 2019-2021
- Figure 97: Glycostem Therapeutics B.V.: Preclinical and Clinical Assets
- Figure 98: ImmunityBio, Inc.: Preclinical and Clinical Assets
- Figure 99: ImmunityBio, Inc.: Overall Financials, $Million, 2019-2021
- Figure 100: ImmunityBio, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 101: ImmunityBio, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 102: Innate Pharma SA: Preclinical and Clinical Assets
- Figure 103: Innate Pharma SA: Overall Financials, $Million, 2019-2021
- Figure 104: Innate Pharma SA: R&D Expenditure, $Million, 2019-2021
- Figure 105: Nkarta, Inc.: Preclinical and Clinical Assets
- Figure 106: Nkarta, Inc.: Overall Financials, $Million, 2019-2021
- Figure 107: Nkarta, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 108: Sanofi S.A.: Preclinical and Clinical Assets
- Figure 109: Sanofi S.A.: Overall Financials, $Million, 2019-2021
- Figure 110: Sanofi S.A.: Revenue (by Segment), $Million, 2019-2021
- Figure 111: Sanofi S.A.: Revenue (by Region), $Million, 2019-2021
- Figure 112: Sanofi S.A.: R&D Expenditure, $Million, 2019-2021
- Figure 113: Takeda Pharmaceutical Company Limited: Preclinical and Clinical Assets
- Figure 114: Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2019-2021
- Figure 115: Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2019-2021
- Figure 116: Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2019-2021
- Figure 117: VaxCell Biotherapeutics Co., Ltd.: Preclinical and Clinical Assets
- Figure 118: Acepodia Inc.: Preclinical and Clinical Assets
- Figure 119: iCell Gene Therapeutics: Preclinical and Clinical Assets
- Figure 120: Senti Biosciences: Preclinical and Clinical Assets
- Figure 121: Shoreline Biosciences: Preclinical and Clinical Assets
- List of Tables
- Table 1: CAR T-Cell Therapy vs. NK Cell Therapy
- Table 2: Advantages and Limitations of NK Cell Therapeutics
- Table 3: Emerging NK Cell Therapeutics Pipeline
- Table 4: Probable Potential First Entrants to Global NK Cell Therapeutics Market
- Table 5: Reimbursement Scenario of CAR T-Cell Therapies in EU5 Countries
- Table 6: Approximate Cost of the Different Types of Immunotherapies
- Table 7: Funding and Investment Activities of the Companies
- Table 8: Partnerships and Collaborations of the Companies
- Table 9: NK Cell Therapy (Unmodified) Pipeline Products
- Table 10: CAR-NK Cell Therapy (Modified) Pipeline Products
- Table 11: NK Cell Engagers Pipeline Products
- Table 12: NK Cell Therapeutics (Pipeline Products) for Acute Myeloid Leukemia
- Table 13: NK Cell Therapeutics (Pipeline Products) for Hepatocellular Carcinoma
- Table 14: NK Cell Therapeutics (Pipeline Products) for T-Cell Malignancies and Peripheral T-Cell Lymphoma
- Table 15: NK Cell Therapeutics (Pipeline Products) for B-Cell Malignancies
- Table 16: List of Key Competitors of Affimed N.V.
- Table 17: List of Key Competitors of Century Therapeutics, Inc.
- Table 18: List of Key Competitors of Celularity Inc.
- Table 19: List of Key Competitors of Cytovac A/S
- Table 20: List of Key Competitors of Dragonfly Therapeutics, Inc.
- Table 21: List of Key Competitors of Fate Therapeutics, Inc.
- Table 22: List of Key Competitors of Gamida Cell Ltd.
- Table 23: List of Key Competitors of GC Cell (GC Biopharma corp.)
- Table 24: List of Key Competitors of Glycostem Therapeutics B.V.
- Table 25: List of Key Competitors of ImmunityBio, Inc.
- Table 26: List of Key Competitors of Innate Pharma SA
- Table 27: List of Key Competitors of Nkarta, Inc.
- Table 28: List of Key Competitors of Sanofi S.A.
- Table 29: List of Key Competitors of Takeda Pharmaceutical Company Limited
- Table 30: List of Key Competitors of VaxCell Biotherapeutics Co., Ltd.
- Table 31: List of Key Competitors of Acepodia Inc.
- Table 32: List of Key Competitors of iCell Gene Therapeutics
- Table 33: List of Key Competitors of Senti Biosciences
- Table 34: List of Key Competitors of Shoreline Biosciences
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
